A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

Primary Sponsor

NCIC Clinical Trials Group (NCIC CTG)

Related Post

28 March, 2025

TROG Awards Recognise Research Excellence

Latest news: 28 March 2025. TROG Members who have

27 March, 2025

TROG 2025 ASM advances inclusivity and innovation

Latest news: 27 March 2025 With a theme of